Arquer, University of Sunderland Collaborate
News Oct 18, 2016
Arquer Diagnostics Ltd (Arquer) has announced that it has signed a collaboration agreement with the University of Sunderland. The partnership aims to investigate non-invasive specimen preparation techniques, which will facilitate the use of Arquer’s MCM5-ELISA test in a wider range of cancers. Arquer’s MCM5-ELISA is a simple, non-invasive test, which has been developed to accurately diagnose both bladder and prostate cancer.
The test works by detecting the presence of minichromosome maintenance complex component 5 (MCM5) protein, a marker for the presence of dividing cancer cells, in urine. MCM proteins are directly involved in cell replication, and are shed into urine by both prostate and bladder tumours. Through the partnership with the University of Sunderland, Faculty of Applied Sciences, Arquer aims to identify the optimal conditions for processing various samples collected using different collection methods to assist in the preparation of a clinical feasibility study in a wider range of cancers.
As part of the collaboration, the University will be carrying out in vitro work, using cell lines, to optimise non-invasive sample collection methods which may be compatible with the MCM5-ELISA. Arquer will supply the MCM5-ELISA tests to enable the University to test the effectiveness of the sampling methods. The study is expected to conclude in early 2017.
Commenting on the partnership, Mr Tristan Sillars, Director of Arquer Diagnostics, said: "As we prepare for EU regulatory submission and market launch of our MCM5-ELISA diagnostic test, we are delighted to be working with the University of Sunderland. The partnership has the potential to extend the application of MCM5-ELISA for use in a wider range of cancers, to benefit both patients and clinicians.”
Arquer recently announced ethical approval for the largest privately funded bladder cancer study in the UK and achieved a key commercial milestone with the announcement of the Companies first manufacturing and supply agreement in February this year.
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE
Infection Blood Test of Limited Value in Reducing Antibiotic UseNews
Overall antibiotic use was not curbed by giving physicians the results of biomarker tests in patients with suspected lower respiratory tract infections, according to findings from the Procalcitonin Antibiotic Consensus Trial (ProACT).READ MORE
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.